Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
Interestingly, our results about OS biomarkers in DM2 and type 1 diabetes mellitus (DM1) showed that antioxidant therapy should not be recommended in DM1 (Nuez-Sells et al., 2019)
Y.CarlsonB
If resistance is felt, gently relieve the vacuum with an empty syringe before adding BAC water
Milovanovic M, Grujicic R
Why this trial matters: First bispecific + CD38 combo to show superior PFS and OS in Phase III in RRMM Potential new standard of care as early as second-line Demonstrates deep responses, high MRD-negativity, and durable outcomes First-line Strategies in BRAF V600E-Mutant mCRC: Real-World Evidence Signals Treatment Priorities In a real-world retrospective cohort of patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), frontline chemotherapy plus anti-VEGF therapy was associated with the longest survival outcomes, while BRAF-targeted strategies showed promising response rates, emphasizing the need for tailored therapy and prospective validation
